AlzeCure Pharma
4.11.2021 10:21:53 CET | ACCESS Newswire | Press release
STOCKHOLM, SE / ACCESSWIRE / November 04, 2021 / AlzeCure Pharma (STO:ALZCUR) (FRA:AC6)
AlzeCure Pharma AB (publ) (FN STO: ALZCUR), a pharmaceutical company that develops a broad portfolio of drug candidates for diseases affecting the central nervous system, with projects in both Alzheimer's disease and pain, today announced that the company is participating at Redeye Life Science Day 2021 on November 11 at 14:30 CEST, where CEO Martin Jönsson will present the company's latest developments. The presentation will be followed by a Q&A with external experts on-site and Redeye's analysts.
The presentation will be held in English and live streamed via https://www.redeye.se/events/815899/redeye-life-science-day-2021 . The recorded presentation and the slide set will also be available afterwards on AlzeCure's website https://www.alzecurepharma.se/en/presentations-and-interviews/ .
For more information, please contact
Martin Jönsson, CEO
Tel: +46 707 86 94 43
martin.jonsson@alzecurepharma.com
About AlzeCure Pharma AB (publ)
AlzeCure® is a Swedish pharmaceutical company that develops new innovative drug therapies for the treatment of severe diseases and conditions that affect the central nervous system, such as Alzheimer's disease and pain - indications for which currently available treatment is very limited. The company is listed on Nasdaq First North Premier Growth Market and is developing several parallel drug candidates based on three research platforms: NeuroRestore®, Alzstatin® and Painless.
NeuroRestore consists of two symptomatic drug candidates where the unique mechanism of action allows for multiple indications, including Alzheimer's disease, as well as cognitive disorders associated with traumatic brain injury, sleep apnea and Parkinson's disease. The Alzstatin platform focuses on developing disease-modifying and preventive drug candidates for early treatment of Alzheimer's disease and comprises two drug candidates. Painless is the company's research platform in the field of pain and contains two projects: ACD440, which is a drug candidate in the clinical development phase for the treatment of neuropathic pain, and TrkA-NAM, which targets severe pain in conditions such as osteoarthritis. AlzeCure aims to pursue its own projects through preclinical research and development to an early clinical phase, and is continually working on business development to find suitable outlicensing solutions with other pharmaceutical companies.
FNCA Sweden AB, +46(0)8 528 00 399 info@fnca.se , is the company's Certified Adviser. For more information, please visit www.alzecurepharma.se .
Image Attachments
Martin Jönsson CEO AlzeCure Pharma
Attachments
AlzeCure presents at Redeye Life Science Day 2021 on November 11
SOURCE: AlzeCure Pharma
View source version on accesswire.com:
https://www.accesswire.com/671149/AlzeCure-Presents-at-Redeye-Life-Science-Day-2021-on-November-11
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.
About ACCESS Newswire
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
ePropelled to Showcase Next Generation Electric Propulsion, Software Innovation and Autonomous Systems Capabilities at Farnborough International Airshow 202617.7.2026 17:00:00 CEST | Press release
Meet the ePropelled team in Hall 2, Stand 2039, on the New Hampshire Mission Pavilion FARNBOROUGH, UK / ACCESS Newswire / July 17, 2026 / ePropelled, a leading global provider of smart propulsion solutions and energy management systems, will exhibit at the Farnborough International Airshow 2026, showcasing its latest innovations for aerospace, defense and uncrewed vehicle applications. Visitors to Hall 2, Stand 2039 on the New Hampshire Mission Pavilion will have the opportunity to meet the ePropelled team and learn about a range of exciting developments, including new product launches, software innovations, technology updates and exclusive previews of next-generation solutions currently in development. With autonomy, electrification and intelligent mobility driving the future of aerospace and defence, ePropelled continues to develop advanced propulsion, power management and software technologies that enhance performance, efficiency and mission capability across air, land and maritime
As the UK Backs Life Sciences and Advanced Manufacturing, US PMO Firm MustardSeed Moves In to Help Deliver It16.7.2026 11:00:00 CEST | Press release
The expansion reflects growing client demand for embedded programme management support across highly regulated industries. WEST CHESTER, PA AND MANCHESTER, UK / ACCESS Newswire / July 16, 2026 / The UK Government's 2025 Modern Industrial Strategy has put life sciences, advanced manufacturing, defence, and clean energy at the centre of Britain's growth agenda. MustardSeed, a US-based programme management and PMO consultancy, is launching UK operations to help organisations in those sectors deliver on that ambition. The 2025 Modern Industrial Strategy names life sciences and advanced manufacturing among its eight priority sectors, alongside defence and clean energy. These are industries defined by complex, regulated, multi-stakeholder programmes where disciplined execution directly determines commercial and operational outcomes. MustardSeed, headquartered in West Chester, Pennsylvania, has built its practice around delivering that execution. The firm announced today the launch of its UK
Akkodis Recognized in the 2026 Gartner(R) Emerging Market Quadrant for Physical AI Services16.7.2026 06:45:00 CEST | Press release
Akkodis continues to advance full-stack engineering expertise and industrial-grade AI deployments. ZURICH, SWITZERLAND / ACCESS Newswire / July 16, 2026 / Akkodis, a global digital engineering consulting company and part of the Adecco Group, has been recognized as a Specialist in the Gartner Emerging Market Quadrant for Physical AI Services (PAIS), published on June 8, 2026. Physical AI services address the complex challenge of designing, developing, deploying and operating AI‑enabled physical systems - such as robots, autonomous systems including, vehicles, drones and industrial infrastructure - in real‑world environments. The Gartner report states "The PAIS market is moving from exploratory experimentation toward operational reliability at scale. This trend is driven by mounting labor constraints, safety requirements, infrastructure modernization and advances in AI, simulation and automation technologies." Full‑stack Physical AI capabilities with real‑world impact and measurable outc
Loar Holdings Inc. Announces Date and Time for Second Quarter 2026 Earnings and Conference Call15.7.2026 22:15:00 CEST | Press release
WHITE PLAINS, NY / ACCESS Newswire / July 15, 2026 / Loar Holdings Inc. (NYSE:LOAR) will report Q2 2026 earnings before the market opens on Thursday, August 6, 2026. A conference call will follow at 11:00a.m. Eastern Time. To participate in the call telephonically please dial +1 877-407-0670 / +1 215-268-9902. International participants can find a list of toll-free numbers here. A live audio webcast will also be available at the following link as well as through the Investor section of Loar Holdings website: https://ir.loargroup.com The webcast will be archived and available for replay later in the day. About Loar Holdings Inc. Loar Holdings Inc. is a diversified manufacturer and supplier of niche aerospace and defense components that are essential for today's aircraft and defense systems. Loar has established relationships across leading aerospace and defense original equipment manufacturers and Tier Ones worldwide. Contact Ian McKillop Loar Holdings Inc. Investor Relations IR@loargro
Fermi Outlines Strategic Rationale for Upsized $431 Million Convertible Notes Offering15.7.2026 14:30:00 CEST | Press release
Flexible convertible structure with shareholder-friendly capped call minimizes dilution Proceeds strengthen liquidity in midst of customer and partner negotiations and preserve Fermi's speed-to-power advantage Attractive five-year cost of capital provides run room to advance multiple commercial tracks in parallel DALLAS, TX / ACCESS Newswire / July 15, 2026 / Fermi Inc. (Nasdaq:FRMI)(LSE:FRMI), operating as Fermi America™ ("Fermi" or the "Company"), outlined today the strategic rationale for its recently closed and upsized offering of $431.25 million aggregate principal amount of 5.00% Convertible Senior Notes due 2031 (the "Notes"), which included the exercise in full of the initial purchasers' 13-day option to purchase up to an additional $56.25 million aggregate principal amount of Notes. The Notes are intended to strengthen Fermi's balance sheet, enhance liquidity, and support continued execution of Project Matador as the Company advances tenant, strategic partnership, and power-de
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom